Medical Xpress: PHYSorg news tagged with: phase 3 http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. Ethics experts call for more thoughtful optimization of drug development process (Medical Xpress)—McGill University post-doctoral fellow Spencer Phillips Hey and Prof. Jonathan Kimmelman, Biomedical Ethics, Social Studies of Medicine, Faculty of Medicine argue that some clinical trials of new drugs need to fail in order to protect study volunteers and healthcare systems. Their work is published this week in the journal Science Translational Medicine. http://medicalxpress.com/news/2013-05-ethics-experts-thoughtful-optimization-drug.html Medications Thu, 09 May 2013 06:50:01 EST news287298829 Healing hormone provides hope for brain injury If Don Stein were the kind of man who listened to what others said, he would have shut down his lab years ago. The Emory neuroscientist spent more than two decades investigating progesterone as a treatment for traumatic brain injury (TBI)—a pursuit that was unappreciated at best and maligned at worst. A naturally occurring hormone was too simple a solution to too complex a problem, according to the prevailing wisdom. http://medicalxpress.com/news/2013-04-hormone-brain-injury.html Medical research Wed, 24 Apr 2013 10:11:03 EST news286017053 Drug does not significantly reduce risk of death among patients with severe sepsis Administration of the drug eritoran to patients with severe sepsis and septic shock failed to demonstrate a significant effect on reducing all-cause 28-day mortality or 1-year mortality, compared with placebo, according to a study in the March 20 issue of JAMA. http://medicalxpress.com/news/2013-03-drug-significantly-death-patients-severe.html Diseases, Conditions, Syndromes Tue, 19 Mar 2013 16:00:13 EST news282927324 Newly approved oral medication slows rheumatoid arthritis joint damage A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month interim analysis of the efficacy of tofacitinib appear in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR). http://medicalxpress.com/news/2013-01-newly-oral-medication-rheumatoid-arthritis.html Arthritis & Rheumatism Thu, 24 Jan 2013 00:00:02 EST news278184294 Teduglutide seems effective, safe for short bowel syndrome (HealthDay)—For patients with short bowel syndrome with intestinal failure (SBS-IF), the glucagon-like peptide 2 analogue teduglutide appears to be safe and reduces the number of days off parenteral support, according to a phase 3 study published in the December issue of Gastroenterology. http://medicalxpress.com/news/2012-12-teduglutide-effective-safe-short-bowel.html Diseases, Conditions, Syndromes Wed, 12 Dec 2012 13:30:01 EST news274540602 New medication shows promise as lipid-lowering therapy for rare cholesterol disorder An international effort led by researchers at the Perelman School of Medicine at the University of Pennsylvania has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder. http://medicalxpress.com/news/2012-11-medication-lipid-lowering-therapy-rare-cholesterol.html Medical research Fri, 02 Nov 2012 09:45:02 EST news271068291 Limiting the problem of missing data urged for clinical trials (HealthDay)—Data missing from clinical trials can undermine the credibility of those trials, and little attention has been focused on this issue until recently, experts say. http://medicalxpress.com/news/2012-10-limiting-problem-urged-clinical-trials.html Medical research Thu, 04 Oct 2012 05:40:01 EST news268546583 New drug might help treat irritable bowel syndrome (HealthDay)—A new drug significantly reduces the abdominal pain and constipation characteristic of certain types of irritable bowel syndrome, according to two new studies. http://medicalxpress.com/news/2012-09-drug-bowel-syndrome.html Diseases, Conditions, Syndromes Tue, 18 Sep 2012 12:20:03 EST news267186928 Phase 3 trial confirms abiraterone acetate efficacy for patients with advanced prostate cancer Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer, which is spreading to other parts of their body (known as metastatic prostate cancer). http://medicalxpress.com/news/2012-09-phase-trial-abiraterone-acetate-efficacy.html Cancer Mon, 17 Sep 2012 18:30:08 EST news267099053 Vitreolytic ocriplasmin resolves vitreomacular traction (HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse events, according to a study published in the Aug. 16 in the New England Journal of Medicine. http://medicalxpress.com/news/2012-08-vitreolytic-ocriplasmin-vitreomacular-traction.html Diseases, Conditions, Syndromes Thu, 16 Aug 2012 18:00:03 EST news264357414 New Herceptin delivery method could vastly simplify breast cancer treatment A new method of delivering a commonly used breast cancer drug could result in considerably less time spent in hospital for some women undergoing breast cancer treatment, according to the results of a Phase 3 trial published Online First in The Lancet Oncology. http://medicalxpress.com/news/2012-08-herceptin-delivery-method-vastly-breast.html Cancer Wed, 08 Aug 2012 18:30:01 EST news263660969 For advanced prostate cancer, new drug slows disease A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results. http://medicalxpress.com/news/2012-06-advanced-prostate-cancer-drug-disease.html Cancer Sat, 02 Jun 2012 04:11:31 EST news257829076 Seasonal changes may influence the efficacy of vaccination against diabetes The development of a medicine for patients with type 1 diabetes mellitus, based on autoantigen GAD65, received a setback following crucial clinical phase 3 trials that failed to show significant effects. One possible explanation may be seasonal variations in the immune system, claim those responsible for the study that was published in the New England Journal of Medicine (NEJM). http://medicalxpress.com/news/2012-02-seasonal-efficacy-vaccination-diabetes.html Diabetes Wed, 01 Feb 2012 17:00:07 EST news247337443 Dual HER2 blockade significantly extends progression-free survival Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo. http://medicalxpress.com/news/2011-12-dual-her2-blockade-significantly-progression-free.html Cancer Thu, 08 Dec 2011 03:53:03 EST news242538772